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Introduction
Pulmonary arterial hypertension (PAH) is a rare, progressive pulmonary vascular disease that has a poor prognosis with a median survival of <3 years if untreated. 1 It can present at any age, including childhood, during which survival is believed to be even worse. 2, 3 Substantial progress has been made in treatment strategies for adult PAH, resulting in improved quality of life and survival. 4, 5 Adult studies alone do not provide a basis for optimal care for children.
However, due to the virtual absence of pediatric efficacy and outcome data, these adult treatment strategies have been extrapolated to children with PAH.
Recently, survival data of pediatric PAH in the current treatment era of PAH-targeted drugs have been reported from different patient cohorts. These include 2 reports on national cohorts of children with PAH from Europe (United Kingdom and the Netherlands) and 2
reports from the United States (US), including 1 study of a cohort of children followed in 2 major US referral centers and 1 of a subgroup of patients with childhood-onset PAH included in a US-based multicenter PAH-registry (REVEAL [Registry to Evaluate Early and Long-Term PAH Disease Management]). [6] [7] [8] [9] [10] In all cohorts, the reported survival seemed to be improved compared to historical reports. However, intriguingly, the reported survival rates appeared to differ significantly between the European and US reports.
No direct comparisons can be made between these reported survival rates due to differences in inclusion criteria, patient characteristics, and data collection. Nevertheless, these discrepancies in survival are of interest, because they might be a consequence of varying patient characteristics or different treatment strategies adopted by the reporting centers. Therefore, they may reveal information on the importance of clinical predictors of survival and on the optimal treatment strategy.
We directly compared patient characteristics, treatment strategies, and outcomes, and identified predictors of outcome in pediatric PAH patients seen on both sides of the Atlantic Ocean, specifically those seen in 2 major referral centers in the United States (New York, New York and Denver, Colorado) and those seen in a national referral center for pediatric PAH based in Europe (the Netherlands) using similar standardized inclusion criteria.
Methods
Patient data were retrospectively collected from 3 major referral centers for pediatric PAH: 2 US-based centers, the Children's Hospital Colorado, Denver, Colorado (Denver cohort) and Columbia University Medical Center, New York, New York (NY cohort) and 1 Europe-based center, the University Medical Center Groningen/Beatrix Children's Hospital, Groningen (Dutch cohort). The Europe-based center serves as the national referral center for pulmonary hypertension (PH) in childhood in the Netherlands. All Dutch children with (suspected) PAH are referred to this center for diagnostic work-up, treatment, and follow-up. It therefore follows a national cohort of children with PAH.
Patients
To define patient cohorts in a way that allowed for direct comparison, we used uniform inclusion criteria: all pediatric PAH (group 1 PH, Dana Point classification 11 ) patients who visited the 3 referral centers between 2000 through 2010, diagnosed by cardiac catheterization at <18 years of age, were included. Diagnosis of PAH was defined as mean pulmonary arterial pressure ≥25 mmHg, mean pulmonary capillary wedge pressure ≤15 mmHg, and pulmonary vascular resistance index (PVRi) ≥3 Wood Units.m². To ensure similar PAH-targeted drug availability for all studied patients, only patients who visited the referral centers between 2000
and 2010 were included. To study a contemporary cohort, only patients diagnosed after 1997
were included. In patients with a corrected heart defect, diagnosis of PAH was confirmed at least 1 year after corrective surgery. 12 Patients who had pulmonary arterial pressures normalized while therapy was discontinued were considered not to have PAH because of the progressive character of the disease, and were not included. To avoid double inclusion, 1 patient who switched from one to the other US center was included in the cohort of the latter center. All patient data were uniformly collected in a database specifically designed for this study.
Patients with PH secondary to left heart disease, lung disease, thromboembolic disease, or PH with unclear multifactorial mechanisms (group 2 to 5 PH, Dana Point classification 11 ) were not included in this study.
Study assessments
Patients were diagnosed according to the Clinical Classification of Pulmonary Hypertension (Dana Point update). 11 For this study, diagnosis was classified as idiopathic or hereditary PAH (IPAH/HPAH), PAH associated with congenital heart disease (PAH-CHD), or associated PAHnon-CHD (APAH-non-CHD). 12 In case of CHD, type of shunt was defined as pre-tricuspid (e.g., atrial septal defect), post-tricuspid (e.g., ventricular septal defect), repaired pre-or repaired post-tricuspid shunt, or as no previous shunt (e.g., coarctation of the aorta). Furthermore, Eisenmenger syndrome was defined as the presence of a post-tricuspid shunt with right-toleft shunting and systemic arterial, or if not available, transcutaneous, oxygen saturation of less than 90%.
Baseline parameters included clinical and hemodynamic characteristics at diagnosis. Agenormalized scores (z-scores) for height and body mass index were calculated using the World Health Organization (WHO) child growth standards. 13, 14 Mean pulmonary-to-systemic arterial pressure ratios (mPAP/mSAP), pulmonary-to-systemic vascular resistance ratios and pulmonary-to-systemic blood flow ratios were calculated. Acute responder status was determined according to criteria defined by the REVEAL study for childhood-onset PAH, Barst et al.
and Sitbon et al. 10, 15, 16 Specific PAH therapy was classified as either calcium channel blocker (CCB) therapy without the need of additional PAH-targeted therapy (CCB monotherapy) or as PAH-targeted therapy, including prostanoids, endothelin receptor antagonists, and type 5-phosphodiesterase inhibitors. PAH-targeted therapy was further classified as monotherapy or as combination therapy with a combination of 2 (dual therapy) or 3 PAH-targeted drugs (triple therapy) administered for at least 3 months or until end of follow-up. Real-time therapy was cumulatively plotted per center cohort for visual comparison. Furthermore, treatment strategy was defined as either CCB monotherapy when a CCB was the only specific PAH drug used during the patient's disease course, or the maximum number of simultaneously used PAH-targeted drugs (mono-, dual, or triple therapy). Also, it was determined whether therapy included an intravenously (IV) or subcutaneously (SC) administered prostanoid. Two Dutch patients and 1
Denver patient were excluded from this latter comparison because their death within 7 days after diagnosis did not allow for start of specific PAH therapy. Survival analyses were based on transplantation-free survival. Patients who did not die or undergo (heart-)lung transplantation were censored at the last recorded visit. For this study, patients who had had their last recorded visit more than 2 years before the end of the study period were considered lost to follow-up.
Statistical analysis
Survival rates were compared between the 3 center cohorts by using Kaplan-Meier curves with log rank testing. Kaplan-Meier curves were also used to illustrate the survival of the patient groups who underwent different treatment strategies. To determine predictors of survival in the total cohort, univariate Cox regression analysis was used. Multivariate backward stepwise Cox regression analysis was used to identify the strongest independent predictors of survival. P-values <0.05 were considered significant.
To assess potential overfitting, we conducted secondary sensitivity analyses using bootstrap model selection to assess independent predictors of survival. This method has been used previously in the context of a population of coronary stent thromboses to avoid an overfit model. 17 Among the variables, bootstrap selection with 500 models was performed in the full dataset only without natriuretic peptides due to the substantial number of missing cases, the full dataset without natriuretic peptides, and blood pressure and, finally the full dataset without natriuretic peptides, blood pressure, and center (see Table 3 ). (5) 8 (6) 3 (3) 2 (4) Asian 23 (8) 17 (13) 4 (4) 2 (4) Hispanic 33 (12) 17 (13) 14 (15) 2 (4) Other or unknown 19 (7) 15 (11) 4 ( (11) 4 (7) 8 (17) 1 (8) Post-tricuspid shunt 54 (47) 30 (56) 13 (28) 11 (85) Repaired pre-tricuspid shunt 6 (5) 2 (4) 4 (9) 0 Repaired post-tricuspid shunt
(31)
17 (32) 17 (36) 1 (8) Eisenmenger syndrome § 14 (12) 7 (13) 3 (6) 4 (31) 0.067 APAH-non-CHD 17 (6) 5 (4) 6 (7) 6 (13) 63 (58) 25 (42) 36 (77) 0.002 ‡ Chest discomfort 29 (13) 22 (20) 5 (9) 2 (4) 0.012 † Fatigue 52 (24) 26 (24) 19 (32) 7 (15) 0.117 Syncope 36 (17) 23 (21) 4 (7) 9 ( 56 (46) 40 (60) 11 (24) III 78 (33) 33 (27) 18 (27) 27 (59) IV 37 (16) 21 (17) 9 (13) 7 (15) Height, cm Value are mean ± SD, median (interquartile range) or n (%).* Post-hoc test with Bonferroni correction shows a p-value <0.05 between the Denver and the NY cohorts. † Post-hoc test with Bonferroni correction shows a p-value <0.05 between the Dutch and the NY cohorts. ‡ Post-hoc test with Bonferroni correction shows a p-value <0.05 between the Dutch and the Denver cohorts. § Of all PAH-CHD patients, separate from shunt types. 6MWD, six-minute walk distance; APAH-non-CHD, associated pulmonary arterial hypertension non congenital heart disease; BMI, body mass index; BNP, brain natriuretic peptide; IPAH/HPAH, idiopathic/hereditary PAH; mPAP, mean pulmonary arterial pressure; mPAP/mSAP, pulmonary-to-systemic arterial pressure ratio; mPCWP, mean pulmonary capillary wedge pressure; mRAP, mean right atrial pressure; mSAP, mean systemic arterial pressure; NT-proBNP, N-terminal pro brain natriuretic peptide; PAH-CHD, PAH associated with congenital heart disease; PVRi, pulmonary vascular resistance index; PVR/SVR, pulmonary-to-systemic vascular resistance ratio; Qpi, pulmonary blood flow index; Qp/Qs, pulmonary-to-systemic blood flow ratio; Qsi, systemic blood flow index; REVEAL, Registry 
Treatment
The 7-year cumulative treatment follow-up of the 3 center cohorts is plotted in Figure 1 . The figure shows that in all 3 center cohorts, there were a similar, stable percentage of patients receiving CCB monotherapy. Considering PAH-targeted therapy, in all 3 cohorts, most patients started on monotherapy, with high percentages of patients on monotherapy within the first 3 years after diagnosis. In time, patients were switched from monotherapy to dual or triple therapy. In all 3 center cohorts a small number of patients received no PAH specific therapy within this 7-year period. These patients either died shortly after diagnosis before therapy could be started, received therapy after 7 years of follow-up, or received no therapy because their low WHO functional classification at that time did not warrant therapy according to evolving treatment strategies. Furthermore, the figure illustrates a higher mortality rate in the Dutch cohort and a higher percentage of patients lost to follow-up in the Denver and NY cohorts. The distribution of treatment strategy did not differ between the center cohorts (Table 2) .
Transplantation-free survival and predictors for prognosis
Follow-up time ranged from 0.01 to 13.7 years (median 4.0 years). During the study period, 7 NY patients (5%), 18 Denver patients (19%), and 15 Dutch patients (32%) died. Furthermore, 6 NY patients (4%) and 1 Dutch patient (2%) underwent lung transplantation. Overall, 1-, 3-, 5-, and 7-year transplantation-free survival rates were 96%, 89%, 81%, and 79%, respectively (Figure 2A ).
Unadjusted survival of children in the NY cohort was significantly more favorable than survival of patients in the other 2 cohorts ( Figure 2B ). Within the Dutch cohort, 33% of the deceased patients died within 3 months after diagnosis versus 6% and 0% of the deceased Denver and NY patients, respectively. Exclusion of these patients did diminish but not completely abolish the survival differences among the center cohorts ( Figure 3A ). Thirty-three NY patients (24%), 6 Denver patients (7%), and 2 Dutch patients (4%) were considered lost to follow-up according to the study methodology (p<0.001). In theory, such patients could favorably bias survival estimates because their potential death during the study period would not be taken into account. To illustrate the maximal effect, we estimated survival rates, hypothesizing that all such patients had died, regardless of any knowledge of these patients' health status after the end of the study period. In this worst-case scenario, no survival difference between the center cohorts was observed ( Figure 3B ). Real-time cumulative percentages of all patients per therapy group were plotted for the NY cohort (A), Denver cohort (B), and Dutch cohort (C). This plot shows the actual percent of patients in a specific therapy group, patients who died, and patients who were censored per follow-up time point. For example, 40% of the NY cohort at diagnosis (time point 0) did not receive any specific PAH therapy; after 1 year, 10% of this cohort received no specific PAH therapy; and after 5 years, 2% received no specific PAH therapy. Legend key is shown in the same descending order as in the figure. PAH, pulmonary arterial hypertension. Kaplan-Meier curves showing the survival (A) for all included pediatric PAH patients: 1-, 3-, 5-, and 7-year transplantation-free survival rates were 96%, 89%, 81%, and 79%, respectively. (B) For all patients stratified by center cohort. 1-, 3-, 5-, and 7-year survival rates were 100%, 96% 90%, and 90% for NY; 95%, 87%, 78%, and 72% for Denver; and 84%, 71%, 62%, and 62% for NL, respectively (p<0.001). Significant survival differences existed between all 3 center cohorts. Without IV/SC prostanoids 51 (19) 28 (21) 13 (14) 10 (22) With IV/SC prostanoids 41 (15) 20 (15) 15 (16) 6 (13) PAH-targeted triple therapy 47 (17) 29 (21) 15 (16) 3 (7) Without IV/SC prostanoids 14 (5) 10 (7) 3 (3) 1 (2) With IV/SC prostanoids 33 (12) 19 (14) 12 (13) 2 (4) Values are presented as n (%). CCB, calcium channel blocker; IV, intravenous; PAH, pulmonary arterial hypertension; SC, subcutaneous.
Acute responders according to the Sitbon criteria had better survival than those who did not meet the Sitbon criteria (p=0.029). The Barst criteria and the REVEAL for childhood-onset PAH criteria did not differentiate between patients with better and worse survival in this population.
Univariate Cox regression analysis (Table 3) shows that compared to children with IPAH/HPAH, those with PAH-CHD had better transplantation-free survival, whereas those with APAH-non-CHD had worse survival. Furthermore, younger age at first symptoms, lower WHO functional class, lower systemic blood pressure, lower plasma N-terminal pro brain natriuretic peptide (NT-proBNP), lower mean right atrial pressure, higher systemic blood flow index, lower PVRi, and lower mPAP/mSAP were associated with better outcome. Sex, ethnicity, Down syndrome, age at diagnosis, syncope, 6-min walk distance, z-scores for height and body mass index, plasma brain natriuretic peptide (BNP), and mean pulmonary arterial pressure were not associated with transplantation-free survival.
NT-proBNP and systolic and diastolic blood pressure were excluded from multivariate analysis because of >20% missing cases. Multivariate backward stepwise Cox regression analysis with the remaining variables that emerged from univariate analysis showed that diagnosis, WHO functional class, PVRi, mPAP/mSAP, and treatment strategy were the strongest independent predictors of transplantation-free survival (Table 4 ). To eliminate a potential effect of PAH-CHD patients with an open shunt for the value of these predictors, we repeated these analyses after exclusion of these 67 patients, which did not change these findings. Also, the findings did not change when accounting for referral center. Kaplan-Meier curves show the survival stratified by center cohort (A) after exclusion of all patients who died within 3 months after diagnosis. Significant survival differences between the NY cohort and the other two cohorts persists. (B) Assuming all patients lost to follow-up died. Now, no significant survival difference could be observed between the center cohorts.
In the total population, during the study period, 5% of patients did not receive any PAH specific therapy, 9% of patients continued on CCB monotherapy, 35% of patients were treated with PAH-targeted monotherapy, and 34% and 17% were treated with dual and triple therapy, respectively ( Table 2 ). Figure 4 shows survival rates stratified by treatment strategy. Patients' disease severity at diagnosis (defined by the identified predictors of survival) is shown in Tables 5 and 6 . Patients receiving CCB monotherapy had significantly better hemodynamics than patients taking PAH-targeted therapy. Patients treated with dual and triple therapy during the study period had a diagnosis of PAH-CHD less frequently, higher mPAP/mSAP and Although the non-use of PAH drugs was associated with worse survival compared to monotherapy in multivariate analysis, we consider the 'no therapy-group' not to be a meaningful control group for patients taking therapy, due to the composition of this group, including both patients with low WHO functional classes doing well without therapy and patients who died shortly after diagnosis. * Hazard ratio per 0.1 change of mPAP/mSAP. † This 'non-treated' group consisted of patients clinically very well without therapy or who died rapidly after diagnosis before therapy could be started. In this statistical analysis, hazard ratio seems determined predominantly by the rapidly dying patients, not doing justice to the patients doing very well without treatment. Therefore this is regarded as not a meaningful hazard ratio. APAH-non-CHD, associated pulmonary arterial hypertension non congenital heart disease; CCB, calcium channel blocker; CI, confidence interval; IPAH/HPAH, idiopathic/hereditary PAH; mPAP/mSAP, pulmonaryto-systemic arterial pressure ratio; PAH-CHD, PAH associated with congenital heart disease; PVRi, pulmonary vascular resistance index; WHO, World Health Organization. Values are mean ± SD or n (%). * P-values for PAH-targeted mono vs. dual vs. triple therapy. † P-values for CCB mono therapy vs. PAH-targeted therapy. APAH-non-CHD, associated pulmonary arterial hypertension non congenital heart disease; CCB, calcium channel blocker; IPAH/HPAH, idiopathic/hereditary PAH; mPAP/mSAP, pulmonaryto-systemic arterial pressure ratio; PAH-CHD, PAH associated with congenital heart disease; PVRi, pulmonary vascular resistance index; WHO, World Health Organization. (24) 20 (39) 12 (86) 13 (65) 32 (78) 25 (76) PAH-CHD 52 (68) 27 (53) 2 (14) 4 (20) 6 (15) 7 (21) APAH-non-CHD 6 (8) 4 (8) 0 3 (15) 3 (7) 1 ( 32 (64) 6 (43) 4 (22) 8 (21) 10 (39) III-IV
(29)
18 (36) 8 (57) 14 (79) 31 (80) 16 ( Values are mean ± SD or n (%). * P-values for PAH-targeted monotherapy versus dual versus triple therapy within the no IV/SC prostanoids used and the IV/SC prostanoids used groups. † P-values for no IV/SC prostanoids used vs. IV/SC prostanoids used. Abbreviations as in Table 5 .
In secondary sensitivity analyses, in which the robustness of the multivariate models was assessed in 3 different datasets, the variables mPAP/mSAP (78 to 89%), diagnosis (63 to 97%) and treatment strategy (50 to 95%) were selected in more than 50% of the models, whereas WHO functional class and PVRi were not.
Discussion
By direct comparison of contemporary patient cohorts from 3 major pediatric PAH referral centers, using standardized inclusion criteria, differences in unadjusted, transplantation-free survival rates were observed. However, adjustment for clinical and hemodynamic patient characteristics, which were identified as predictors of survival in the total cohort, resolved the survival differences among the center cohorts. Independent of these patient-related predictors, treatment with combination therapy with PAH-targeted drugs during the study period was associated with better survival than treatment with monotherapy with a PAH-targeted drug.
Parameters associated with survival
Children with APAH-non-CHD had significantly worse survival, whereas those with PAH-CHD showed favorable survival compared to IPAH/HPAH patients. This is congruent with several previous reports, although discrepant data have also been reported that show similar survival rates for pediatric PAH-CHD and IPAH/HPAH patients. 6, 7, 9, 18 These reported discrepancies may be due to the heterogeneity of the heart defects that underlie PAH-CHD (e.g., closed versus open shunts, simple versus complex defects) for which survival rates may differ. 18 Further studies are needed on this issue.
WHO functional class is a non-invasive but subjective assessment of clinical condition that is widely used to predict outcome and guide therapy in adult PAH. 1, 19 Its applicability in pediatric PAH has been debated as WHO functional class may be difficult to assess in infants and Kaplan-Meier curves show survival stratified by treatment strategy (A) for all patients; (B) for patients who did not receive intravenous/subcutaneous prostanoids; and (C) for patients who did receive intravenous/ subcutaneous prostanoids. PAH, pulmonary arterial hypertension.
young children. However, various major referral centers for pediatric PAH have independently shown WHO functional class to be an important predictor of outcome, which was confirmed in the primary analysis in this study. [7] [8] [9] 20 Secondary sensitivity analyses in the current study could not confirm the robustness of WHO functional class as an independent predictor. This
indicates that further studies, in addition to the current study, are needed to confirm the robustness of WHO functional class as independent predictor of outcome in pediatric PAH.
A functional classification system customized for young children has been proposed but has yet to be validated. 21 The hemodynamic parameters independently associated with survival in this study have previously been identified as predictors of outcome in other, mostly single-center studies. 7, 10, 22 Hemodynamic parameters have the advantages of objectivity and obtainability at any age.
However, an important disadvantage is the need of a cardiac catheterization procedure, which often requires anesthesia or sedation in infants and young children with associated risks. In contrast to the Barst and REVEAL for childhood-onset PAH criteria, acute responders according to the Sitbon criteria had better survival than non-responders in this study, confirming previous reports. 22 Therefore, the Sitbon criteria seems to be applicable also in children and may better predict long-term survival in pediatric PAH.
In the current study, the natriuretic peptides BNP and NT-proBNP were available at diagnosis only for a small number of patients. We could not demonstrate an association between BNP and survival. However, despite low numbers, NT-proBNP was associated with survival, confirming previous reports. 9, 23, 24 Due to these low numbers, NT-proBNP could not be included in multivariate analysis, limiting its evaluation as an independent predictor. However, on the basis of the currently available literature, the authors feel that NT-proBNP should be part of the standardized follow-up for children with PAH and be included in future studies in order to adequately assess its value as an independent predictor of survival in pediatric PAH.
Other parameters, which have been previously reported to be associated with survival in pediatric PAH, such as age at diagnosis and z-score for height, were not associated with survival in the current study.
10,20

Survival differences among the center cohorts
There were relatively more IPAH/HPAH and APAH-non-CHD patients in the Dutch cohort compared to the US cohorts, which attributed to the observed survival differences.
Based on WHO functional class and hemodynamics, children in the Dutch cohort appeared to have more severe disease than children in the US cohorts. Also, the proportion of patients lost to follow-up, which differed among the center cohorts, may attribute to the observed survival differences. In a hypothetical worst-case scenario, where all patients lost to follow-up are assumed dead (obviously representing an overestimate of the number of deaths), a survival difference between the center cohorts could not be demonstrated.
Treatment patterns, as defined for this study (CCB mono therapy or PAH-targeted monotherapy, dual or triple therapy), did not differ between the center cohorts and, thus, did not contribute to the survival differences between the center cohorts.
Treatment
Our findings confirm that, like in adult PAH, in pediatric PAH a small select subgroup of patients (with favorable hemodynamics) has a favorable, long-term survival on CCB monotherapy without the need of additional PAH-targeted therapy. 25 In this study, treatments with PAH-targeted dual and triple therapy during the study period were associated with better survival than treatment with PAH-targeted monotherapy, whether or not treatment strategy included IV/SC prostanoids. Differences in disease severity at diagnosis could not explain the observed survival differences among patients taking monotherapy or dual and triple therapy. Patients who received IV/SC prostanoid therapy had more severe disease at diagnosis. These data also illustrate that IV/SC prostanoids as monotherapy may not suffice in children with severe disease and is associated with poor outcome.
Therefore, this study provides additional support for the notion of a more aggressive treatment approach in pediatric PAH, with the use of combination therapy. Given the relatively large proportion of patients receiving monotherapy found in all 3 center cohorts, there may be room for improvement in this respect. Whether an initial or an add-on treatment strategy would be most beneficial to improve outcome in pediatric PAH patients should be further evaluated.
A goal-oriented treatment strategy aiming at predefined improvement of the clinical condition instead of reacting to deterioration of the patient's clinical condition and leading to intensification of treatment has been suggested to improve outcome in adult PAH. 26, 27 Such a strategy is likely to be beneficial also in pediatric PAH. However, in contrast to adult PAH, treatment goals to guide goal-oriented treatment are neither well defined nor validated in pediatric PAH. 12 The parameters identified to predict survival in this study may qualify for such treatment goals in the future. However, further research is essential to establish and validate treatment goals and to determine the effects of a goal-oriented treatment strategy on survival in this vulnerable patient population.
Study limitations
Retrospective studies come with certain limitations. However, the 3 center cohorts that were brought together come from 3 PAH-dedicated centers with standardized diagnostic and treatment protocols, minimizing these limitations. Multivariate analysis was limited by missing values within specific parameters that may be caused by either different diagnostic and follow-up strategies among centers or by the inherent impossibility to obtain certain data in certain age or patient groups. In the analyses regarding treatment strategy, individual variations in doses and time relationships were not taken into account, precluding definitive conclusions on a causal relationship between treatment strategy and outcome. To address the risk of overfitting in this relatively small study, we performed secondary sensitivity analyses, in which the variables diagnosis, mPAP/mSAP, and treatment strategy were confirmed to be independent predictors of outcome, whereas WHO functional class and PVRi could not be confirmed in these secondary analyses, indicating that their robustness as independent predictors of outcome should be further studied. Diagnostic cardiac catheterizations were performed under both general anesthesia and conscious sedation. A potential effect of the mode of anesthesia on hemodynamics was not investigated in this study. Furthermore, the moderately high altitude of Denver was not taken into account in this study and may have negatively biased the outcome of the Denver cohort. Bringing together the complete consecutive patient cohorts of 3 major referral centers for pediatric PAH provided a unique opportunity to validate clinical patient characteristics that appeared to be responsible for observed survival differences and to find clues to optimize and guide therapy.
Conclusions
Unadjusted survival rates of pediatric PAH patients differed among 3 major referral centers.
This study identified diagnosis, WHO functional class, mPAP/mSAP and PVRi as independent predictors of outcome that could explain the observed survival differences among the center cohorts. Moreover, we found that treatment with PAH-targeted combination therapy during the study period was independently associated with improved transplantation-free survival.
Secondary sensitivity analyses indicated that the robustness of WHO functional class and PVRi as predictors of outcome in pediatric PAH deserves further evaluation.
